Apatinib is an oral tyrosine kinase inhibitor of VEGFR2, which exhibited promising anti-neoplastic and antiangiogenic and activities in certain tumors, such as breast carcinoma [7], sarcoma [8], hepatocellular carcinoma [9], non-small-cell lung cancer [10], and recurrent epithelial ovarian cancer [11]. This evidence concerns the gene KDR and hepatocellular carcinoma.